The 4D imaging capability of LUMA's Verafeye is expected to improve clinical decision-making and reduce risks associated with a range of cardiac procedures. Credit: Jo Panuwat D via Shutterstock. · ...

Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) are currently up over 20.6% after the company released positive results from its Spectra trial. The Spectra trial evaluates 4D-150 in patients with ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio PARK CITY, Utah — In this Healio Video ...

DUBLIN & MUNICH--(BUSINESS WIRE)--LUMA Vision, developer of a novel four-dimensional (4D) cardiac imaging and navigation platform, today announced a total of $22 million in new financing for the ...

New features in Apera Vue 9.50 help manufacturers and integrators adapt to real-world variation, boost precision, and accelerate deployment of 4D Vision-Guided Robotic systems—no vision expertise ...

LUMA Vision Ltd, an innovative leader in advanced cardiac imaging and navigation, announced the US FDA clearance for its Verafeye Visualization Platform. This novel catheter-based imaging system ...

Scientists in Hong Kong and mainland China have developed a wearable device to release aromas as cinema-goers enjoy a 4D movie, students learn about a new plant or doctors help patients recall ...